

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4564951

| | |
|---|------------------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION | 08/22/2017 |
| RECEIVING PARTY DATA | |
| Name: | INTRON BIOTECHNOLOGY, INC. |
| Street Address: | 1013, 137, SAGIMAKGOL-RO |
| Internal Address: | JUNGWON-GU, SEONGNAM-SI |
| City: | GYEONGGI-DO |
| State/Country: | KOREA, REPUBLIC OF |
| Postal Code: | 13202 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Application Number: | 15521222 |
| CORRESPONDENCE DATA | |
| Fax Number: | (415)576-0300 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | 4155760200 |
| Email: | dgibby@kilpatricktownsend.com |
| Correspondent Name: | KILPATRICK TOWNSEND & STOCKTON LLP |
| Address Line 1: | 1100 PEACHTREE STREET |
| Address Line 4: | ATLANTA, GEORGIA 30309 |
| ATTORNEY DOCKET NUMBER: | 96275-1046964 |
| NAME OF SUBMITTER: | DARIN J. GIBBY |
| SIGNATURE: | /darin j gibby/ |
| DATE SIGNED: | 08/24/2017 |
| Total Attachments: 4 | |
| source=96275-1046964-assignment#page1.tif | |
| source=96275-1046964-assignment#page2.tif | |
| source=96275-1046964-assignment#page3.tif | |
| source=96275-1046964-assignment#page4.tif | |

**PATENT AND PATENT APPLICATION ASSIGNMENT
COMPANY TO COMPANY**

This ASSIGNMENT is made by Seoul National University R&DB Foundation, having a business address at 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea (hereinafter "ASSIGNOR") to iNtRON Biotechnology, Inc., having a business address at 1013, 137, Sagimakgol-ro, Jungwon-gu, Seongnam-si, Gyeonggi-do 13202, Republic of Korea (hereinafter "ASSIGNEE").

WHEREAS, ASSIGNOR is the owner of record of United States Patent Application No. 15/521,222, entitled

"NOVEL PEPTIDE COMPOUND, PRODUCTION METHOD THEREFOR, AND USE THEREOF,"

filed with the U.S. Patent & Trademark Office on April 21, 2017, hereinafter the '222 Application;

WHEREAS, ASSIGNOR wishes to assign, and **ASSIGNEE** wishes to acquire, the '222 Application;

NOW THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, **ASSIGNOR** hereby

1. Agrees to assign, transfer, convey, and sell to **ASSIGNOR** the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, and all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
 - (c) the right to claim priority to the above-referenced patent application, and any and all applications referenced in subsection (b); and
 - (d) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications

ASSIGNMENT

U.S. Patent Application No. 15/521,222

described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and

(e) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.

2. Authorizes and requests the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
3. Agrees to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon Assignor as well as its legal representatives, and assigns.

IN WITNESS WHEREOF, ASSIGNOR has caused this Assignment to be executed as of the date below written.

ASSIGNOR:

Seoul National University R&DB Foundation

By: Kim Yong Geun

Name: KIM, YONG GEUN

Title: Assistant Director

Date: August 22, 2017

ASSIGNEE:

iNtRON Biotechnology, Inc.

By: _____

Name: _____

Title: _____

Date: _____

**PATENT AND PATENT APPLICATION ASSIGNMENT
COMPANY TO COMPANY**

This ASSIGNMENT is made by Seoul National University R&DB Foundation, having a business address at 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea (hereinafter "ASSIGNOR") to iNtRON Biotechnology, Inc., having a business address at 1013, 137, Sagimakgol-ro, Jungwon-gu, Seongnam-si, Gyeonggi-do 13202, Republic of Korea (hereinafter "ASSIGNEE").

WHEREAS, ASSIGNOR is the owner of record of United States Patent Application No. 15/521,222, entitled

"NOVEL PEPTIDE COMPOUND, PRODUCTION METHOD THEREFOR, AND USE THEREOF,"

filed with the U.S. Patent & Trademark Office on April 21, 2017, hereinafter the '222 Application;

WHEREAS, ASSIGNOR wishes to assign, and ASSIGNEE wishes to acquire, the '222 Application;

NOW THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR hereby

1. Agrees to assign, transfer, convey, and sell to ASSIGNOR the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, and all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
 - (c) the right to claim priority to the above-referenced patent application, and any and all applications referenced in subsection (b); and
 - (d) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications

ASSIGNMENT

U.S. Patent Application No. 15/521,222

described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and

- (e) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.
2. Authorizes and requests the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
 3. Agrees to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
 4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon Assignor as well as its legal representatives, and assigns.

IN WITNESS WHEREOF, ASSIGNOR has caused this Assignment to be executed as of the date below written.

ASSIGNOR:

Seoul National University R&DB Foundation

By: _____

Name: _____

Title: _____

Date: _____

ASSIGNEE:

iNtRON Biotechnology, Inc.

By: AS _____

Name: Kang Sang Hyeon

Title: Vice President

Date: Aug 25, 2017